![Rachel Reiff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rachel Reiff
No más puestos en curso
Perfil
Rachel Reiff worked as the Head of Corporate Communications at Aratana Therapeutics, Inc.
Antiguos cargos conocidos de Rachel Reiff.
Empresas | Cargo | Fin |
---|---|---|
ARATANA THERAPEUTICS INC | Public Communications Contact | 01/10/2019 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Aratana Therapeutics, Inc.
![]() Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
- Bolsa de valores
- Insiders
- Rachel Reiff